138 related articles for article (PubMed ID: 21154746)
21. Tsp2 Facilitates Tumor-associated Fibroblasts Formation and Promotes Tumor Progression in Retroperitoneal Liposarcoma.
Xu C; Yan L; Guan X; Wang Z; Wu J; Lv A; Liu D; Liu F; Dong B; Zhao M; Jia L; Tian X; Hao C
Int J Biol Sci; 2022; 18(13):5038-5055. PubMed ID: 35982904
[TBL] [Abstract][Full Text] [Related]
22. Surgical management of primary undifferentiated pleomorphic sarcoma of the rectum: a case report and review of the literature.
Kodera K; Hoshino M; Takahashi S; Hidaka S; Kogo M; Hashizume R; Imakita T; Ishiyama M; Ogawa M; Eto K
World J Surg Oncol; 2022 Jun; 20(1):199. PubMed ID: 35698131
[TBL] [Abstract][Full Text] [Related]
23. Tyrosine kinase inhibitors in sarcoma treatment.
Kyriazoglou A; Gkaralea LE; Kotsantis I; Anastasiou M; Pantazopoulos A; Prevezanou M; Chatzidakis I; Kavourakis G; Economopoulou P; Nixon IF; Psyrri A
Oncol Lett; 2022 Jun; 23(6):183. PubMed ID: 35527786
[TBL] [Abstract][Full Text] [Related]
24. Molecular targeted therapy for advanced or metastatic soft tissue sarcoma.
Yuan J; Li X; Yu S
Cancer Control; 2021; 28():10732748211038424. PubMed ID: 34844463
[TBL] [Abstract][Full Text] [Related]
25. The timing of targeted therapy initiation in metastatic sarcoma as an adjuvant to first-line chemotherapy or a second-line agent.
Huang Y; He A; Tang L; Cheng X; Shen Z; Yao Y; Min D
Am J Transl Res; 2021; 13(8):9095-9103. PubMed ID: 34540023
[TBL] [Abstract][Full Text] [Related]
26. Biology and Management of Dedifferentiated Liposarcoma: State of the Art and Perspectives.
Nishio J; Nakayama S; Nabeshima K; Yamamoto T
J Clin Med; 2021 Jul; 10(15):. PubMed ID: 34362013
[TBL] [Abstract][Full Text] [Related]
27. VEGFR Inhibitors for Uterine Metastatic Perivascular Epithelioid Tumors (PEComa) Resistant to mTOR Inhibitors. A Case Report and Review of Literature.
Liapi A; Mathevet P; Herrera FG; Hastir D; Sarivalasis A
Front Oncol; 2021; 11():641376. PubMed ID: 33842348
[TBL] [Abstract][Full Text] [Related]
28. Treatment options in unresectable soft tissue and bone sarcoma of the extremities and pelvis - a systematic literature review.
Smolle MA; Szkandera J; Andreou D; Palmerini E; Bergovec M; Leithner A
EFORT Open Rev; 2020 Nov; 5(11):799-814. PubMed ID: 33312707
[TBL] [Abstract][Full Text] [Related]
29. Novel Therapeutic Insights in Dedifferentiated Liposarcoma: A Role for FGFR and MDM2 Dual Targeting.
Dadone-Montaudié B; Laroche-Clary A; Mongis A; Chamorey E; Mauro ID; Chaire V; Finetti P; Schiappa R; Le Loarer F; Birtwisle-Peyrottes I; Michiels JF; Bertucci F; Pedeutour F; Italiano A; Bianchini L
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33092134
[TBL] [Abstract][Full Text] [Related]
30. Genetic aberrations and molecular biology of cardiac sarcoma.
Urbini M; Astolfi A; Indio V; Nannini M; Pizzi C; Paolisso P; Tarantino G; Pantaleo MA; Saponara M
Ther Adv Med Oncol; 2020; 12():1758835920918492. PubMed ID: 32489430
[TBL] [Abstract][Full Text] [Related]
31. Atypical Presentation of Renal Leiomyosarcoma: A Case Report.
Darlington D; Anitha FS
Cureus; 2019 Aug; 11(8):e5433. PubMed ID: 31632881
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of apatinib in treatment of osteosarcoma after failed standard multimodal therapy: An observational study.
Tian Z; Gu Z; Wang X; Liu Z; Yao W; Wang J; Zhang P; Cai Q; Ge H
Medicine (Baltimore); 2019 May; 98(19):e15650. PubMed ID: 31083265
[TBL] [Abstract][Full Text] [Related]
33. miR-193b regulates tumorigenesis in liposarcoma cells via PDGFR, TGFβ, and Wnt signaling.
Mazzu YZ; Hu Y; Shen Y; Tuschl T; Singer S
Sci Rep; 2019 Mar; 9(1):3197. PubMed ID: 30824765
[TBL] [Abstract][Full Text] [Related]
34. Safety and Tolerability of Anti-Angiogenic Protein Kinase Inhibitors and Vascular-Disrupting Agents in Cancer: Focus on Gastrointestinal Malignancies.
Procaccio L; Damuzzo V; Di Sarra F; Russi A; Todino F; Dadduzio V; Bergamo F; Prete AA; Lonardi S; Prenen H; Palozzo AC; Loupakis F
Drug Saf; 2019 Feb; 42(2):159-179. PubMed ID: 30649744
[TBL] [Abstract][Full Text] [Related]
35. Diagnosis and Treatment of Myxoid Liposarcomas: Histology Matters.
Abaricia S; Hirbe AC
Curr Treat Options Oncol; 2018 Oct; 19(12):64. PubMed ID: 30362022
[TBL] [Abstract][Full Text] [Related]
36. Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm.
Arend RC; Toboni MD; Montgomery AM; Burger RA; Olawaiye AB; Monk BJ; Herzog TJ
Oncologist; 2018 Dec; 23(12):1533-1545. PubMed ID: 30139839
[TBL] [Abstract][Full Text] [Related]
37. Treatment-related adverse effects with pazopanib, sorafenib and sunitinib in patients with advanced soft tissue sarcoma: a pooled analysis.
Que Y; Liang Y; Zhao J; Ding Y; Peng R; Guan Y; Zhang X
Cancer Manag Res; 2018; 10():2141-2150. PubMed ID: 30050324
[TBL] [Abstract][Full Text] [Related]
38. Positive correlation between the density of macrophages and T-cells in undifferentiated sarcoma.
Komohara Y; Takeya H; Wakigami N; Kusada N; Bekki H; Ishihara S; Takeya M; Nakashima Y; Oda Y
Med Mol Morphol; 2019 Mar; 52(1):44-51. PubMed ID: 29980952
[TBL] [Abstract][Full Text] [Related]
39. Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas.
Nakano K; Takahashi S
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29510588
[TBL] [Abstract][Full Text] [Related]
40. Radiotherapy in soft-tissue sarcoma of the extremities.
Correa R; Gómez-Millán J; Lobato M; Fernández A; Ordoñez R; Castro C; Lupiañez Y; Medina JA
Clin Transl Oncol; 2018 Sep; 20(9):1127-1135. PubMed ID: 29476322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
